Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | KZR |
---|---|---|
09:32 ET | 406 | 0.5885 |
09:38 ET | 100 | 0.5711 |
09:39 ET | 100 | 0.5711 |
09:41 ET | 380 | 0.572 |
09:43 ET | 100 | 0.5725 |
09:45 ET | 100 | 0.5725 |
09:48 ET | 100 | 0.5826 |
09:50 ET | 1100 | 0.57755 |
09:52 ET | 100 | 0.5725 |
09:54 ET | 1588 | 0.5826 |
09:56 ET | 38065 | 0.57565 |
09:59 ET | 100 | 0.5711 |
10:01 ET | 100 | 0.5713 |
10:06 ET | 100 | 0.5713 |
10:08 ET | 300 | 0.574 |
10:10 ET | 100 | 0.5713 |
10:14 ET | 300 | 0.5765 |
10:17 ET | 100 | 0.5735 |
10:21 ET | 20000 | 0.579332 |
10:28 ET | 100 | 0.5726 |
10:32 ET | 100 | 0.5729 |
10:37 ET | 100 | 0.5729 |
10:39 ET | 10000 | 0.579 |
10:42 ET | 100 | 0.5729 |
10:44 ET | 100 | 0.5729 |
10:46 ET | 100 | 0.5729 |
10:48 ET | 100 | 0.57595 |
10:50 ET | 100 | 0.5729 |
10:53 ET | 200 | 0.5729 |
10:57 ET | 300 | 0.57435 |
11:02 ET | 100 | 0.57435 |
11:04 ET | 100 | 0.5743 |
11:06 ET | 1450 | 0.57325 |
11:08 ET | 250 | 0.574 |
11:09 ET | 1300 | 0.5725 |
11:13 ET | 100 | 0.5725 |
11:15 ET | 2500 | 0.571 |
11:18 ET | 300 | 0.57105 |
11:22 ET | 200 | 0.57105 |
11:26 ET | 100 | 0.57105 |
11:27 ET | 100 | 0.57105 |
11:31 ET | 1400 | 0.5711 |
11:36 ET | 100 | 0.57215 |
11:40 ET | 100 | 0.57215 |
11:47 ET | 100 | 0.57215 |
11:49 ET | 300 | 0.5732 |
11:54 ET | 100 | 0.57215 |
11:56 ET | 200 | 0.5733 |
12:03 ET | 100 | 0.5721 |
12:07 ET | 2558 | 0.57165 |
12:09 ET | 200 | 0.57165 |
12:14 ET | 100 | 0.57165 |
12:18 ET | 200 | 0.5716 |
12:20 ET | 100 | 0.5716 |
12:23 ET | 324 | 0.57 |
12:30 ET | 100 | 0.57 |
12:32 ET | 100 | 0.5716 |
12:34 ET | 100 | 0.57 |
12:38 ET | 1204 | 0.5701 |
12:39 ET | 100 | 0.5701 |
12:43 ET | 100 | 0.5701 |
12:45 ET | 2276 | 0.5731 |
12:48 ET | 1422 | 0.5779 |
12:54 ET | 100 | 0.57415 |
01:12 ET | 100 | 0.5703 |
01:14 ET | 100 | 0.5703 |
01:15 ET | 100 | 0.5703 |
01:17 ET | 100 | 0.5779 |
01:19 ET | 100 | 0.5703 |
01:21 ET | 272 | 0.574 |
01:26 ET | 100 | 0.574 |
01:28 ET | 1028 | 0.57405 |
01:32 ET | 100 | 0.5703 |
01:33 ET | 100 | 0.574 |
01:37 ET | 900 | 0.574 |
01:39 ET | 200 | 0.574 |
01:42 ET | 100 | 0.5703 |
01:48 ET | 100 | 0.5703 |
01:50 ET | 173 | 0.5775 |
01:51 ET | 100 | 0.57395 |
01:53 ET | 100 | 0.5703 |
01:57 ET | 200 | 0.5703 |
02:02 ET | 200 | 0.5728 |
02:04 ET | 100 | 0.5703 |
02:08 ET | 400 | 0.5703 |
02:11 ET | 1607 | 0.5703 |
02:13 ET | 1076 | 0.5717 |
02:18 ET | 100 | 0.5702 |
02:22 ET | 100 | 0.5702 |
02:26 ET | 100 | 0.5702 |
02:29 ET | 100 | 0.5702 |
02:36 ET | 500 | 0.5773 |
02:38 ET | 7100 | 0.57375 |
02:40 ET | 4024 | 0.5727 |
02:44 ET | 200 | 0.5702 |
02:49 ET | 100 | 0.5702 |
02:54 ET | 100 | 0.5702 |
02:58 ET | 100 | 0.5702 |
03:02 ET | 100 | 0.5702 |
03:05 ET | 272 | 0.5702 |
03:14 ET | 200 | 0.5737 |
03:16 ET | 100 | 0.5702 |
03:20 ET | 200 | 0.5736 |
03:23 ET | 100 | 0.5702 |
03:25 ET | 200 | 0.5703 |
03:30 ET | 100 | 0.5703 |
03:32 ET | 100 | 0.5703 |
03:34 ET | 610 | 0.5702 |
03:36 ET | 100 | 0.57355 |
03:38 ET | 100 | 0.5702 |
03:39 ET | 873 | 0.571 |
03:41 ET | 463 | 0.5702 |
03:43 ET | 990 | 0.5702 |
03:45 ET | 100 | 0.5702 |
03:48 ET | 300 | 0.5702 |
03:50 ET | 100 | 0.5702 |
03:52 ET | 3519 | 0.5701 |
03:54 ET | 400 | 0.5701 |
03:56 ET | 300 | 0.5701 |
03:57 ET | 600 | 0.5702 |
03:59 ET | 109502 | 0.5706 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Kezar Life Sciences Inc | 42.5M | -0.4x | --- |
LAVA Therapeutics NV | 44.2M | -1.8x | --- |
DURECT Corp | 42.5M | -2.5x | --- |
Atara Biotherapeutics Inc | 44.9M | -0.2x | --- |
Kronos Bio Inc | 57.1M | -0.6x | --- |
Bolt Biotherapeutics Inc | 24.1M | -0.4x | --- |
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). Its oncology product candidate, KZR-261, is a small molecule agent, targeting the Sec61 translocon and protein secretion pathway, being studied in an open-label Phase I clinical trial designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, as well to explore preliminary anti-tumor activity. This study is being conducted in two parts: dose escalation in patients with locally advanced or metastatic solid malignancies, and dose expansion in patients with selected tumor types.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $42.5M |
---|---|
Revenue (TTM) | $7.0M |
Shares Outstanding | 73.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.20 |
EPS | $-1.35 |
Book Value | $2.58 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | 6.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,531.57% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.